These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23146910)

  • 1. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
    Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
    J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
    Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
    Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Yoden T; Okada M; Fujikura T; Akaza H; Shikama H
    Prostate; 1998 Sep; 37(1):10-8. PubMed ID: 9721064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
    Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
    Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
    Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
    Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orteronel for the treatment of prostate cancer.
    Van Hook K; Huang T; Alumkal JJ
    Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
    Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
    Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
    Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
    Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
    Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
    Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
    Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.
    Rampurwala M; Wisinski KB; Burkard ME; Ehsani S; O'Regan RM; Carmichael L; Kim K; Kolesar J; Tevaarwerk AJ
    Invest New Drugs; 2017 Feb; 35(1):87-94. PubMed ID: 27826831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
    Roviello G; Pacifico C; Chiriacò G; Generali D
    Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
    Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prochloraz inhibits testosterone production at dosages below those that affect androgen-dependent organ weights or the onset of puberty in the male Sprague Dawley rat.
    Blystone CR; Furr J; Lambright CS; Howdeshell KL; Ryan BC; Wilson VS; Leblanc GA; Gray LE
    Toxicol Sci; 2007 May; 97(1):65-74. PubMed ID: 17234647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.
    Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Fujikura T; Akaza H; Shikama H
    Jpn J Pharmacol; 1999 Feb; 79(2):213-20. PubMed ID: 10202857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.